Skip Navigation

Staff Detail

Skip sharing on social media links

​​​

Zajicek, ANNE

Formal Title:

Chief, OPPB, CRMC

Responsibilities:

The Obstetric and Pediatric Pharmacology and Therapeutics Branch supports research in pediatric and obstetric clinical pharmacology. This encompasses basic, translational, and clinical pharmacology in children and pregnant women,including developmental pharmacology, pharmacogenomics, pharmacoepidemiology, and research related to development of pediatric dosage forms.

Phone:

301-435-6865

Email:

zajiceka@mail.nih.gov

Address:

6100 EXECUTIVE BLVD Room 4A01B, MSC 7510
Bethesda Md 20892-7510
For FedEx use:
Rockville Md 20852

Biosketch:

Anne Zajicek, M.D., Pharm.D., is a board-certified pediatrician and pediatric clinical pharmacologist who currently serves as Chief of the Obstetric and Pediatric Pharmacology and Therapeutics Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). She received a Bachelor’s degree in Pharmacy from Duquesne University and a PharmD from the State University of New York at Buffalo; completed a postdoctoral fellowship in the Department of Pharmaceutics of St. Jude Children’s Research Hospital; and served as an assistant professor at the University of Colorado School of Pharmacy and a Clinical Pharmacist at National Jewish Hospital and Research Center. In 1991, Dr. Zajicek entered medical school at the University of Pittsburgh, and, in 1998, completed a residency in pediatrics at the Children’s Hospital of Pittsburgh. She practiced primary care pediatrics for 2 years and then continued her training as a pediatric clinical pharmacology fellow at Stanford University. She subsequently joined the U.S. Food and Drug Administration (FDA) in the Office of Clinical Pharmacology and Biopharmaceutics. She joined NICHD as a Pediatric Medical Officer in August 2003, and was appointed Chief of the Obstetric and Pediatric Pharmacology and Therapeutics Branch in 2010.  The Branch is responsible for the NIH implementation of the Best Pharmaceuticals for Children Act. The Branch manages a portfolio of grants in obstetric and pediatric pharmacology training and basic, translational and clinical research. 

Publications (PubMed):

Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.
Drug studies in newborns: a therapeutic imperative.
We don't know what we don't study: the case for research on medication effects in pregnancy.
Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.
Special challenges in comparative effectiveness research on children's and adolescents' health.
Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.
The National Institutes of Health and the Best Pharmaceuticals for Children Act.
Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.
Gaps in knowledge in treating pregnant women.
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology